Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Polymorphisms in estrogen receptor alpha (ESR1) are reported to be associated with the susceptibility to persistent HBV infection, HBV liver cirrhosis and HBV-related hepatocellular carcinoma (HCC).
Materials and methods
To test the hypothesis that polymorphisms in estrogen receptor alpha (ESR1) might influence the virological response to entecavir (ETV) therapy, we examined two polymorphisms (PvuII and XbaI) in 76 nucleoside-naïve chronic hepatitis B (CHB) patients. All of the patients (52 HBeAg-positive and 24 HBeAg-negative) were treated with ETV 0.5 mg daily and followed up for a median time of 96 weeks (range 48–96). Polymorphisms were determined using the polymerase chain reaction–restriction fragment-length polymorphism (PCR–RFLP) method.
Under an additive model, the univariate analysis showed that patients carrying the PvuII T/C genotype might have higher virological responders than those carrying the T/T and C/C genotypes at week 48 (87.7 vs. 57.1 vs. 58.3 %; P = 0.012) and week 96 (96.7 vs. 64.3 vs. 24 87.5 %; P = 0.018), although this difference disappeared with the multiple analysis at week 48 [95 % confidence interval (CI) 0.687–3.841; P = 0.269] and week 96 (95 % CI 0.861–18.016; P = 0.077). Conversely, the univariate analysis suggests statistical significance between the recessive model of PvuII (TT vs. TC/CC) and virological response at week 48 (57.1 vs. 81.1 %; P = 0.033) and week 96 (64.3 vs. 94.7 %; P = 0.017). Multiple regression analysis affirmed the significant and independent association between the recessive model of PvuII and virological response. In other words, patients carrying at least one PvuII C allele (TC/CC) had a better likelihood of achieving virological response compared with those carrying the T/T genotype at week 48 (95 % CI 1.026–14.785, P = 0.046) and week 96 (95 % CI 1.456–57.509; P = 0.018). XbaI polymorphisms were not significantly associated with virological response.
Our results suggest that the PvuII polymorphism may play an important role in determining ETV efficacy after 48 and 96 weeks of treatment, at least in this study population.
- Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500. CrossRef
- Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309–19. CrossRef
- Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–83. CrossRef
- Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39. CrossRef
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67. CrossRef
- Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection—the German guideline. Z Gastroenterol. 2011;49:871–930. CrossRef
- Muneer B, Testa G, Millis JM, Mohanty SR. Entecavir therapy in a hepatitis B-related decompensated cirrhotic patient. South Med J. 2008;101:1173–6. CrossRef
- Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45:1172–8. CrossRef
- Lee JS, Park ET, Kang SS, Gu ES, Kim JS, Jang DS, et al. Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients. Intervirology. 2010;53:83–6. CrossRef
- Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, et al. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol. 2012;53:130–4. CrossRef
- Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B. Ann Hepatol. 2011;10:434–40.
- Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Lee DH, et al. Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B. Korean J Hepatol. 2010;16:57–65. CrossRef
- Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, et al. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17:268–73. CrossRef
- Deng G, Zhou G, Zhai Y, Li S, Li X, Li Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology. 2004;40:318–26. CrossRef
- Zhai Y, Zhou G, Deng G, Xie W, Dong X, Zhang X, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology. 2006;130:2001–9. CrossRef
- Zhang TT, Zhang ZH, Gao YF, Zhang YF, Yang DL, Li X. T29C genotype polymorphism of estrogen receptor alpha is associated with initial response to interferon-alpha therapy in chronic hepatitis B patients. Hepatobiliary Pancreat Dis Int. 2010;9:275–9.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97. CrossRef
- Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16:269–77. CrossRef
- Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94. CrossRef
- Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854–63. CrossRef
- Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol. 2011;46:1111–7. CrossRef
- Yan Z, Tan W, Xu B, Dan Y, Zhao W, Deng C, et al. A cis-acting regulatory variation of the estrogen receptor alpha (ESR1) gene is associated with hepatitis B virus-related liver cirrhosis. Hum Mutat. 2011;32:1128–36. CrossRef
- Cohn CS, Sullivan JA, Kiefer T, Hill SM. Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer. Mol Cell Endocrinol. 1999;158:25–36. CrossRef
- Iwashita S, Koyama K, Nakamura Y. VNTR sequence on human chromosome 11p15 that affects transcriptional activity. J Hum Genet. 2001;46:717–21. CrossRef
- Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2000;2:360–6. CrossRef
- Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids. 2000;65:227–51. CrossRef
- Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239–47. CrossRef
- Wang SH, Yeh SH, Lin WH, Yeh KH, Yuan Q, Xia NS, et al. Estrogen receptor alpha represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4alpha. Gastroenterology. 2012;142:989–998.e4. CrossRef
- Tong S. Hepatitis B virus, a sex hormone-responsive virus. Gastroenterology. 2012;142:696–9. CrossRef
- Marcellin P, Liang J. A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antivir Ther. 2010;15:53–9. CrossRef
- Bihl F, Loggi E, Chisholm JV 3rd, Biselli M, Morelli MC, Cursaro C, et al. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. Liver Transpl. 2008;14:478–85. CrossRef
- Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol. 2006;3:97–106.
- Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology. 2007;361:141–8. CrossRef
- Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006;87:1439–49. CrossRef
- Milich DR, Schödel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol. 1997;71:2192–201.
- Okasha SA, Ryu S, Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology. 2001;163:49–62. CrossRef
- Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. 2004;173:2227–30.
- Jiang Y, Li W, Yu L, Liu J, Xin G, Yan H, et al. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol. 2011;8:75–82. CrossRef
- Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, et al. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese. Antiviral Res. 2012;93:297–300. CrossRef
- Zhu X, Du T, Wu X, Guo X, Niu N, Pan L, et al. Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B. Antiviral Res. 2011;89:189–92. CrossRef
- Ren S, Yu H, Zhang H, Liu Y, Huang Y, Ma L, et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res. 2011;89:232–7. CrossRef
- Wang S, Huang D, Sun S, Ma W, Zhen Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa. Virol J. 2011;8:28. CrossRef
- Wu X, Zhu X, Zhu S, Li J, Ma J, Li Z, et al. A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. Antiviral Res. 2009;83:252–6. CrossRef
- Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, et al. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion. 2011;84:35–42. CrossRef
- Park YK, Lee JM, do Kim Y, Chang HY, Kim JK, Lee CK, et al. Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B. Dig Dis Sci. 2010;55:2043–8. CrossRef
- Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis. 2011;31:115–27. CrossRef
- Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B
Volume 41, Issue 2 , pp 371-378
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Chronic hepatitis B
- Industry Sectors
- Author Affiliations
- 1. Department of Infectious Diseases, First Affiliated Hospital, Anhui Medical College, Hefei, 230022, China
- 2. Department of Infectious Diseases, Second Affiliated Hospital, Anhui Medical College, Hefei, 230601, China